Navigation Links
ChemGenex in Medical News

ChemGenex's omacetaxine may provide first viable treatment option for highly resistant form of CML

... MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 1st, 2009) chemgenex Pharmaceuticals Limited (ChemGenex) (ASX:CXS) announced that the latest data from its pivotal study of omacetaxine in patients with T315I-positive chr...

Arete Therapeutics Appoints Donald Santel to Board of Directors

...quired by Boston Scientific. Mr. Santel began his career at Medtronic, Inc. Currently, Mr. Santel also serves on the board of Anthera Pharmaceuticals, chemgenex Pharmaceuticals, and Hyperion Therapeutics. He has a BSE from Purdue University and an MS in from the University of Minnesota. About Arete Therapeut...

ChemGenex Treats First Patient With Ceflatonin

... Melbourne-based chemgenex Pharmaceuticals has treated the first patient in a new phase II/III clinica...rolled into CML-203 at the MD Anderson Cancer Center in Houston, Texas, and chemgenex is expanding the study to an estimated 15 centers through the United States...

Scientists Hopeful of a Cure for Diabetes

...s has long been considered as a lifestyle disease linked to a poor dietary habits and sedentary lifestyle. The gene was unearthed by the chemgenex Pharmaceuticals team from Geelong providing scientists worldwide with the much-needed impetus to develop new tests and drugs for diabetes. ChemG...

Genetics helps in attacking cancer

... genes, which may help refine future treatments. Ceflatonin, a natural product, is being tested as an anti-cancer treatment. Meanwhile, the US company chemgenex is looking at the effect of the drug on the genes that are activated in cancer. They find that specific genes and cellular pathways are affected by ce...
ChemGenex in Medical Technology

Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (May 21, 2007): ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) notes the publication of new clinical data relevant to the development strategy for Ceflatonin® (homoharringtonine). The paper "Targeted therapy and the T315I mutation in ...

Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex

MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--May 21, 2007 - ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) notes the publication of new clinical data relevant to the development strategy for Ceflatonin(R) (homoharringtonine). The paper "Targeted therapy and the T315I mutation...

ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO

...MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 4, 2007 - chemgenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced..., Chief Executive Officer and Managing Director of chemgenex said that the results were a significant step in t...mark of ChemGenex Pharmaceuticals Limited. About chemgenex Pharmaceuticals Limited (www.chemgenex.com) ...

ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO

..., Chief Executive Officer and Managing Director of chemgenex said that the results were a significant step in t...mark of ChemGenex Pharmaceuticals Limited. About chemgenex Pharmaceuticals Limited ( (function() { var po = document.createElement('script'); po.type = 'text/javascript'; po.async = true; po.src = 'https://apis.google.com/js/plusone.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(po, s); })();